Impel: Reroute Migraine Relief
A new vision for migraine relief
The situation:
Migraine is a crowded market with multiple classes of medications. We were tasked with launching an old yet effective drug - DHE - but delivered in an innovative technology that provided the medicine to the upper nasal space for rapid absorption. We needed to establish the need for non-oral treatment options in migraine while also creating attention for data supporting the value/role of TRUDHESA.
The idea and execution:
To create the unmet need and amplify the role of the brain/gut connection, we launched Reroute Migraine Relief, featuring the work of a portrait artist who brought to life the complexities of migraine through his commissioned artwork. Activations included a website, media launch with SMT/RMT, and boosted social posts to his many Instagram followers. In conjunction, we’ve amplified numerous data milestones related to the prevalence of brain/gut connection and the safety and exploratory efficacy of TRUDHESA. and efficacy data from Impel’s pivotal STOP 301 trial before the upcoming FDA approval.
The results:
72 million earned media impressions
78k social impressions
over 26 media interviews
over 37k visits to the website housing the campaign
